|
Kai
Sun, Department of Hepatobiliary Surgery, Xijing Hospital,
Xi’an 710032, Shaanxi province, China
Bo-Quan Jin, Yong Zhu, Kun Yang, Xue-Song Liu, Bang-Quan Dong,
Department of Immunology, The Fourth Military Medical University,
Xi’an 710032, Shaanxi province, China
Qi Feng, Department of Hematology, Xijing Hospital; Xi’an
710032, Shaanxi province, China
Supported by the National Nature Science Foundation. No
39700065
Correspondence to: Kai Sun, M.D, Department of Hepatobiliary
Surgery, Xijing Hospital, Xi’an 710032, Shaanxi province, China. iamsunkai@263.net
Telephone: +86-029-3242969 Fax: +86-029-3242969
Received 2001-06-11 Accepted 2001-10-16
Abstract
AIM:
To
confirm the existence of CD226 ligand and its distribution, which is
a novel molecule that was cloned in 1996.
METHODS:
The
mRNA was extracted from TPA activated Jurkat cells and used as a
template for reverse-transcription. After PCR amplification, the
fragment including CD226 extracellular region and the splice donor
sequence “ACTTACCTGT” was obtained and cloned into fusion
expression vector pIG. The recombinant vector pCD226/Ig was
transfected in COS-7 cells by DEAE-Dextran method, the secreting
fusion protein was identified by Sandwich ELISA, and was purified by
anti-CD226 affinity chromatography. This fusion protein was used as
a probe in the investigation of CD226 ligand by immunohistochemistry.
Existence of CD226 ligand was further identified by adhesion
experiment.
RESULTS:
Expression of a secreting fusion protein was identified by sandwich
ELISA, indicating that both CD226 extracellular domain and IgGFc
domain could be recognized respectively by anti-CD226 and anti-hIgFc
mAb. About 130μg CD226/Ig fusion protein could be obtained from
100mL COS-7 culture supernatants by anti-CD226 affinity
chromatography purification. SDS-PAGE showed that this fusion
protein has a molecular mass of 83 ku. It was confirmed by
immunohistochemistry that CD226 ligand expressed on the Colo205
cells, but not on Jurkat cell, U937 cell and mixed lymphocyte
culture cells. In adhesive assay, resting Jurkat cells did not have
significant adhesion to Colo205 cells. In contrast, activated Jurkat
cells could bind to colon carcinoma Colo205 cells and this adhesive
reaction could be blocked by CD226/Ig fusion protein or anti-CD226
mAb. Immunochemical experiment showed that Colo205 cells could be
specifically stained by CD226/Ig, indicating that CD226 ligand
exists on the surface of Colo205 cells.
CONCLUSION:
Existence of CD226 ligand on the surface of Colo205 cells was
identified by immunohistochemistry and adhesion blocking experiment.
In addition, the secreting CD226/Ig fusion protein prepared in this
study will be a potential tool for further investigation of CD226
ligand.
Sun K,
Jin BQ, Feng Q, Zhu Y, Yang K, Liu XS, Dong BQ. Identification of
CD226 ligand on colo205 cell surface. World J Gastroenterol
2002;8(1):108-113
INTRODUCTION
CD226
was initially reported by Burns in 1985 with a name TLiSA1 (T
lineage specific activation antigen 1, TLiSA1)[1], and
was renamed PTA1 (platelet and T cell antigen 1, PTA1) in 1989
because of its expression on platelet as well[2]. Since
1985, a lot of investigations have been done on CD226 expression,
functions and its relationship with diseases[2-6]. CD226
was mainly expressed on the activated T cells, NK cells, monocytes,
platelets and megakaryocytes lineage[4-8], taking part in
signal transduction of T cell activation and differentiation as well
as platelet activation and aggregation. CD226 mAb was found to
stimulate the activation and aggregation of platelets[2,3],
inhibit differentiation of CTL[2,9]and T and NK cell
mediated cytotoxicity[7]. In 1997, PTA1 cDNA was cloned
from cDNA library of TPA activated Jurkat cells[10]. It
belongs to an immunolglobulin super family (IgSF) with a 232aa
extracellular region, 25aa transmembrane region and 61aa
intracellular region. Interestingly, PTA1 cDNA was almost the same
as that of DNAM-1 (DNAX associated molecule-1), a novel molecule
cloned by Shibuya in 1996[7]. In 2000, PTA1 (DNAM-1) was
designated as CD226 on the 7th Workshop and Conference on the Human
Leucocyte Differentiation Antigen in Harrogate. CD226 is the only
IgSF member whose extracellular region consists of two IgV-like
domains.
Almost
all the important Ig-superfamily members are highly conserved during
molecular evolution[11-13], such as CD2, CD4/CD8 and
CD28. Homological analysis showed that CD226 molecules are highly
conserved (93%-95%) among human, ape and monkey, suggesting that
CD226 may have very important functions[14]. It seems
that CD226 takes part in the mechanism of platelet function
disorders, autoimmune diseases, transplantation, virus infection
diseases and tumors[3,15-20], suggesting that CD226 plays
an important role in immune system and may have a potential
application to clinical diagnosis and treatment. Up to, little is
known about CD226 ligand. So, the aim of this study is to make a
preliminary research on CD226 ligand.
MATERIAL
AND METHODS
Materials
pIG vector was a gift kindly presented by Dr. Xu. COS-7, U937,
Jurkat, Colo205 cell line and CD226 hybridoma (secreting mAb Leo-A1
against the extracellular domain of CD226) were provided by Prof.
Jin. Goat anti-human Ig-SABC immunohistochemistry kit was purchased
from Boster Co. Vectors and restrict enzymes were purchased from
Huamei Co; Trizol reagent kit was purchased from Gibco Co, and
CNBr-Sepharose 4B is a product of Pharmacia Co.
Design
of the primers for semi-nest RT-PCR
Primers were designed according to the sequence of CD226 cDNA:
primer 1, 5’-GCAAGCTTCAGAGATGGATTATCCTACT-3’ (forward,
containing HindIII enzyme site at 5’); primer 2, 5’-
GCGGATCCACTTACCTGTAGCCACAAAGAGGGTATATTGG-3’ (reverse, containing
BamHIenzyme site and donor splice region “ACTTACCTGT” at 5’);
primer 3, 5’- ACTCTAGTCTTTGGTCCTGC-3’. Primer1 and Primer 3 were
used to amplify the whole length CD226 cDNA, and primer 1 and primer
2 were used to amplify cDNA encoding CD226 extracellular region
(Figure 1).
Figure
1(PDF) Sequence
of CD226 cDNA and primers. 174-923bp: extracellular region of CD226;
174-227bp: signal peptide sequence; 924-998bp: transmembrane region;
□labeled
sequence: primers; underlined sequence was the splicing donor
sequence.
Reverse
transcription-polymerase chain reaction (RT-PCR)
Jurkat cells were cultured at a concentration of 1×109·L-1
with TPA (50μg·L-1) for 18-30 h at 37℃,
and the total RNA was isolated by Trizol reagent kit. RNA was primed
and reverse transcribed into cDNA in a 20μL reaction volume
containing 10U reverse transcriptase, 10μg RNA, 10×Buffer 2μL,
10mmol·L-1 dNTP complex 4μL, and primer 3. After
incubation at 42℃
for 1 h, the reverse transcription product was PCR amplified by
Primer 1 and Primer 3, and then by Primer 1 and Primer 2. The PCR
parameters were 94℃
for 1 min, 60℃
for 1 min, and 72℃
for 80 s for 35 cycles.
Plasmid
construction
Expression vector for CD226 extracellular region was prepared as
previously described[21]. The corresponding PCR fragment
was cloned into pUC-19 and M13mp18/19 vector for DNA sequencing.
After DNA sequencing, the 793bp fragment encoding CD226
extracellular region and the splice donor sequence “ACTTACCTGT”
was subcloned into pIG, a mammalian fusion protein expression vector
containing the cytomegalovirus (CMV) promoter, splice acceptor,
genomic human IgG1, and SV40 polyadenylation signal. The resulting
expression vector pCD226/Ig was identified by PCR and restrict
enzyme digestion.
COS-7
cell Transfection
COS-7 cell transfection was performed by a modified method[22].
Briefly, COS-7 cells at 50%-75% confluence were transfected in 7mL
glucose Dulbecco’s modified Eagle’s medium (DMEM) containing
100mL·L-1 fetal calf serum (FCS), 400μg
DEAE-dextran/mL, 100 μmol·L-1 chloroquine
diphosphate, and 40 μg purified DNA. After 3 h at 37℃,
the transfection mixture was removed and the cells were treated with
100g·L-1 dimethyl sulfoxide in PBS for 2 min. Cells were
then returned to DMEM supplemented with 10mL·L-1 fetal calf serum (FCS)
for 4 d to allow CD226/Ig expression.
Purification and identification of CD226/Ig fusion protein
Leo-A1 affinity chromatography column was prepared as previously
described[23]. The pCD226/Ig transfected COS-7
supernatant was spined out cell debris for 5 minutes at 10000 r·min-1,
filtered through a 0.45μm filter and then purified by Leo-A1
affinity chromatography. The expression of a secreting fusion
protein was identified by sandwich ELISA (anti-CD226 mAb and HRP-conjugated
anti-hIg mAb, anti-IL-8 antibody was used as control). SDS-PAGE and
Western-blot (polyclonal anti-hIgG antibody) were performed by
routine methods.
Immunohistochemical
staining by CD226/Ig
Immunohistochemical experiment was performed by SABC methods. For
light microscopy, cytospin preparations of Colo205 cells were
incubated with 3g·L-1 methanol-hydrogen peroxide
solution at 37℃
for 30 min to inactivate endogenous peroxidases. The slides were
then blocked in goat serum blocking solution at 37℃
for 30 min. Without washing, the slides were incubated with CD226/Ig
fusion protein (10mg·L-1) at 4℃.
After overnight incubation, the slides were washed three times with
PBS, and incubated with biotin labeled goat anti human IgG for 4 h
at room temperature. Finally, the slides were washed, allowed to sit
for 2 min, and then reacted with SABC complex and DAB peroxidase
substrate solution. Human IgG1 was used instead of CD226/Ig in the
control experiment.
Adhesion
assay
In 96 well plate, Colo205 cells with the density of 0.5×105/well
were cultured for one day to let cells confluence, and 3.7 MBq 51Cr
labeled resting or activated Jurkat cells were added with 1×105/well
and cultured for 4 h, and non-adhered cells were moved by gently
washing, the adhered cells were lysed by 20g·L-1 Triton
X-100, and Bq was measured. Different concentrations of CD226/Ig
fusion protein and anti-CD226 mAb Leo-A1 were used in the adhesion
blocking experiment.
RESULTS
Construction
of pCD226/Ig fusion expression vector
A very low level of CD226 molecules was expressed on resting Jurkat
cells, and the expression level could be enhanced by TPA stimulation
for 24 h. The CD226 mRNA from Jurkat cells was enriched by TPA
stimulating. After retro-transcription, semi-nests PCR
amplification, a single band about 800bp has been obtained. This
fragment was then ligated into pUC19 and subcloned into M13mp18/19
vector for sequencing. The sequencing data showed that the fragment
was 793bp long in total, a HindIII enzyme site could be found at the
upstream and the “ACTTACCTGT”donor splicing sequence and a BamHI
site could be found at the downstream. The 793 bp fragment was
ligated between HindIII and BamHI sites of pIG vector. The
recombinant vector pCD226/Ig was identified by restrict enzyme
digestion assay and PCR identification (Figure 2).
Figure
2(PDF)
Construction of pCD226/Ig fusion vector.
Expression,
identification and purification of CD226/Ig fusion protein
The pCD226/Ig vector was transiently transfected into COS-7 cells.
The optimal conditions was checked before large-scale transfection,
and it was found that transfected COS-7 cells cultured in medium
with 10ml·L-1 serum for 96 h could produce CD226/Ig most
effectively. The secreted CD226/Ig fusion protein was purified by
Leo-A1 affinity chromatography, About 130μg CD226/Ig fusion
protein could be obtained from 100mL COS-7 culture supernatants by
anti-CD226 affinity chromatography purification. SDS-PAGE showed
CD226/Ig fusion protein has a molecular mass of 83 ku (Figure 3) and
could be recognized by anti-IgG polyclonal antibody in Western-blot
assay (Figure 4). In ELISA assay, CD226/Ig expression could be
identified in pCD226/Ig transfected COS-7 supernatant, but a
negative result was obtained in pIG vector transfected COS-7
supernatant (Table 1). Both CD226 extracellular domain and Fc domain
of the CD226/Ig protein could be recognized respectively by
anti-CD226 and anti-hIg Fc mAb, suggesting that CD226/Ig could mimic
the nature CD226 molecule and be a potential tool in the research of
CD226 ligand and its functions.
Figure
3 Identification
of CD226/Ig fusion protein purified by Leo-A1 Sepharose-4B affinity
column. 1. Supernatant of pIG vector transfected COS-7 cells; 2.
Supernatant of pCD226/Ig transfected COS-7 cells; 3. Supernatant of
pCD226/Ig transfected COS-7 cells after concentrated by ammonium
sulfate; 4. Flow through solution of pCD226/Ig transfected COS-7
cells after affinity chromatography; 5. CD226/Ig fusion protein
purified by Leo-A1 sepharose-4B affinity column; 6. Marker.
Figure
4 Western-blot
result of CD226/Ig by anti-IgG polyclonal antibody Lane 1.
Supernatant of pCD226/Ig transfected COS-7 cells;
Lane
2. Supernatant of pIG transfected COS-7 cells
Table
1 Identification
of CD226/Ig fusion protein expression by sandwich-ELISA
|
Coated
antibody
|
Samples
tested
|
Conjugated
secondary antibody
|
Results
|
|
Anti-CD226
|
pCD226/Ig
transfected COS supernatant
|
HRP-GαhIgG
|
+++
|
|
Anti-CD226
|
pIG
transfected COS supernatant
|
HRP-GαhIgG
|
-
|
|
Anti-IL-8
|
pCD226/Ig
transfected COS supernatant
|
HRP-GαhIgG
|
-
|
Identification
of CD226 ligand on Colo205 cells
Immunohistochemical experiment showed that Colo205 cells could be
specifically stained by CD226/Ig but not by control protein (hIgG),
indicating that CD226 ligand exists on the surface of Colo205 cells
(Figure 5). Resting Jurkat cells had a low-level expression of CD226
on cell surface, whereas activated Jurkat cells expressed high level
of CD226 after TPA treatment for 24h. In adhesive assay, resting
Jurkat cells have a very low level adhesion to Colo205 cells. In
contrast, activated Jurkat cells could bind to colon carcinoma
Colo205 cells and this adhesive reaction could be blocked by CD226/Ig
fusion protein or Leo-A1 mAb but not control Ig and anti-IL-1 mAb,
indicating that CD226 takes part in this specific adhesion (Figure
6).
Figure
5
CD226L expression on Colo205 cells identified by CD226/Ig
immunohistochemistry. A: Colo205 negative control (stained with hIg);
B: Colo205 cells were specifically stained by CD226/Ig.
Figure
6(PDF)
Adhesion experiments of activated Jurkat cells with Colo205 cells.
Density of Colo205 was 0.5×105 per well. Density of
Jurkat was 1×105 per well. R stand for resting Jurkat
cells. A stand for activated Jurkat cells.
DISCUSSION
CD226 is a 65 ku glycoprotein expressed on the surface of
activated T cells, NK cells, and platelets. It is a member of the
Ig-superfamily containing 2 Ig-like domains of the V-set and is
encoded by a gene on human chromosome 18q22.3[24].
Ig-superfamily members play essential roles in many aspects of
immune responses by acting as immunoglobulin Fc receptors, cytokine
receptors, adhesive molecules and accessory molecules[11,25-27].
The main function of Ig-super family concentrated in cell-to-cell
recognition and interaction, such as LFA-1/CD2, CD4/MHC, CD28/B7,
and many of these Ig-super family members are involved in the T cell
activation[28-32]. Cross-linking CD226 with antibodies
cause the activation of T cells and aggregation of platelets.
Previous studies also showed the cross-linking of LFA-1 induced
tyrosine phosphorylation of CD226, in which the Fyn protein tyrosine
kinase may play a role[33,34]. The above results indicate
that CD226 mediates cellular adhesion to other cells bearing an
unidentified ligand and takes part in signal transduction.
Interaction between ligand and receptor is the basis of immune
response. So, identification of CD226L is very important for the
further investigation of CD226.
Intercellular
adhesive molecules play an important role in the immune response,
they provide not only intercellular binding, but also participate in
signal transduction, and are closely related with allograft
rejection, tolerance, cell differentiation, lymphocyte homing and
tumor immunity[35-39]. In addition to the specific
antigen recognition signal provided by CD3-TCR complex, a lot of
other signals are required in the T cells mediated immune response,
such as signals provided by CD4/CD8, CD2, LFA-1, CD28[40-42].
Our previous results showed that resting T cells expressed low-level
of CD226 molecule. When T cells were activated, they expressed
high-level CD226 molecules. This finding suggested that CD226 might
be closely related to the function of activated T cells.
Differentiation of T cell to CTL could be inhibited when Leo-A1 mAb
or Leo-A1 F(ab’)2 were added into mixed lymphocyte
culture (MLC), and production of LAK cells was also reduced, this
action of Loe-A1 was not dependent on Fc of Leo-A1. The inhibiting
effect of Loe-A1 only works in the differentiation phase of CTL but
not in the cytotoxicity phase, suggesting that the epitope
recognized by CD226 is related with the differentiation of CTL[1,2,7].
Another mAb DX11 against CD226 (DNAM-1) was reported to
significantly inhibit the cytotoxicity of CTL to several tumor cell
lines, such as Colo205, PA-1, MCF7[7]. Therefore, epitope
recognized by DX11 mAb was different from that recognized by Leo-A1
mAb, and these two different epitopes may take part in the
differentiation and cytotoxicity of CTL.
Since
the mid 1980s, there has been a rapid increase in our knowledge
about the specific cell surface molecules mediating cell-cell
interaction and adhesion events. This has been largely due to the
success of molecular cloning techniques, allowing the isolation of
functional cDNA clones that encoding these glycoproteins. Always
methods have been successfully used in the cloning of novel cDNA.
One of these methods reported by Aruffo and Seed is very effective[43,44].
This method is based on the transient expression of cDNA library in
cells and specific mAb recognition (capture and panning). Several
molecules, such as CD2, CD22, CD28, CD36 and CD58 [43-47],
have been cloned by this method. So, once a suitable antibody,
ligand or cell line has been identified to recognize a cell surface
molecule, the cDNA encoding this molecule could be cloned by this
method. CD226 molecule or its homologue to be used in the
investigation of CD226 ligand should have the following
characteristics: easy to obtain, high in purity and natural in
motif. So these molecules could be obtained by purification from
platelet, preparations of anti-idiotype mAb or preparations of
recombinant CD226 molecule. In this study, we prepared the CD226/Ig
fusion protein containing CD226 extracellular region 232aa
(including 10 glycosylation sites, 57ku) and IgG Fc region (CH2, CH3
and H region, 26ku), the putative molecule weight is consistent with
that identified in SDS-PAGE and Western-blot. CD226/Ig fusion
protein is expressed in secreting form that was detected by
Sandwich-ELISA, its two different domains could be recognized by
anti-CD226 mAb and anti-hIg Fc mAb, respectively, but could not be
recognized by other mAb, suggesting CD226/Ig can mimic the nature of
CD226 molecule and can be used in the research of CD226 ligand. Ig
fusion proteins have many advantages such as easy to purify, easy to
label and easy to detect, and thus were widely used in ligand
identification[48-53], and disease protection[54-56].
These advantages make it more convenient to further clone CD226
ligand.
Immunohistochemical research suggested that CD226 ligand was
expressed on Colo205 cells and this result was also supported by
adhesion-blocking experiment. It was shown that resting Jurkat cells
expressed very low level of CD226 molecules, but activated Jurkat
cells expressed high-level CD226 molecules after TPA activation for
24 h, and the expression of CD226 was regulated by cytokines, such
as TGF-β, TNF-α and IL-2[57]. In the experiment
about adhesion, activated Jurkat cells could bind to colon carcinoma
Colo205 cells and this adhesion reaction could be blocked by CD226/Ig
fusion protein or Leo-A1 mAb but not by control Ig and anti-IL-1 mAb,
indicating that CD226 ligand exist in Colo205 cells and takes part
in this specific adhesion.
When T cells were activated, they expressed high-level CD226
molecules. Interestingly, CD226 ligand seemed to express on the
surface of tumor cells. Activated T cells not only need the specific
antigen recognition by TCR, but also the engagement of accessory
molecules on T cells by their respective ligans expressed on the
target cells[38,39,58,59]. More researches need to be
done to reveal their relationship and what signal have CD226
transducted during immune response against tumors. The above results
made a solid foundation for further cloning of CD226 ligand and is
helpful for thorough investigations on CD226L structure and
function.
ACKNOWLEDGMENT
We
would like to thank Dr. Xu and Dr. Lan for their valuable technical
advice and assistance.
REFERENCES
1
Burns GF, Triglia T, Werkmeister JA, Begley CG, Boyd AW. TLiSA, a
human T lineage-specific activation antigen involved
in the
differentiation of cytotoxic T lymphocytes and anomalous killer
cells from their precursors. J Exp Med
1985;
161: 1063-1078
2 Scott JL, Dunn SM, Jin B, Hillam AJ, Walton S,
Berndt MC, Murray AW, Krissansen GW, Burns GF. Characterization of
a
novel membrane
glycoprotein involved in platelet activation. J Biol Chem 1989; 264:
13475-13482
3 Zuzel M, Walton S, Burns GF, Berndt MC, Cawley
JC. A monoclonal antibody to a 67 kD cell membrane glycoprotein
directly
induces persistent platelet aggregation independently of
granule secretion. Br J Haematol 1991;79:466-473
4 Sun Chen, Jin Boquan, Liu Xuesong, Yang Kun,
Zhang Tingting, Dong Bangquan, Li Jiazeng, Wu huaizhu, Peng Lin, Bao
Chengxin, Wu
Wenjie. PTA1 monoclonal antibody induce human platelet aggregation
and intra-cytoplasmic Ca2+
elevation.
Zhonghua Xue Ye Za Zhi
1998;19:133-137
5 Li Demin, Jin Boquan, Su Li, Jia Wei, Sun Kai,
Liu Xuesong, Zhang Tingting. Distribution and function of murine
platelets
and
T cell activation
antigen 1. Zhonghua Wei Sheng Wu Xue He Mian Yi Xue Zha Zhi
1999;19:232-235
6 Sun Kai, Feng Qi, Jin Boquan. Platelet and T
cell antigen 1 (PTA1). Zhonghua Wei Sheng Wu Xue He Mian Yi Xue Zha
Zhi
1999;19:261-264
7 Shibuya A, Campbell D, Hannum C, Yssel H, Franz
Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR,
Lanier
LL, Phillips JH. DNAM-1,
A Novel Adhesion Molecule Involed in the Cytolytic Function of T
Lymphocytes. Immunity
1998:
4: 573-581
8 Slupsky JR, Cawley JC, Kaplan C, Zuzel
M.Analysis of CD9, CD32 and p67 signalling: use of degranulated
platelets
indicates direct
involvement of CD9 and p67 in integrin activation. Br J Haematol
1997;96:275-286
9 Chen LK, Bensussan A, Burns GF, Tourvieille B,
Soulie A, Sasportes M. Allospecific proliferative human T-cell
clones
acquire
the cytotoxic effector
function after three months in culture, in IL-2 conditioned medium.
Hum Immunol
1986;17:30-36
10 Sherrington PD, Scott JL, Jin B, Simmons D, Dorahy DJ,
Lloyd J, Brien JH, Aebersold RH, Adamson J, Zuzel M, Burns GF.
TLiSA(PTA1)
activation antigen implicated in T cell differentiation and platelet
activation is a member of the regulation
of
expression. J Biol Chem 1997; 272: 21735-21744
11 Halaby DM, Mornon JP. The immunoglobulin superfamily: an
insight on its tissular, species, and functional diversity.
J
Mol Evol 1998;46:389-400
12 Hawke NA, Yoder JA, Litman GW. Expanding our understanding
of immunoglobulin, T-cell antigen receptor, and novel
immune-type
receptor genes: a subset of the immunoglobulin gene superfamily.
Immunogenetics 1999;50:124-133
13 Ioerger TR, Du C, Linthicum DS. Conservation of cys-cys trp
structural triads and their geometry in the protein
domains
of immunoglobulin superfamily members. Mol Immunol 1999;36:373-386
14 Tian Fang, Li Demin, Xia Haibin, Liu Xuesong, Jia Wei, Sun
Chen, Sun Kai, Jin Boquan. Isolation of cDNAs Encoding
Gibbon
and Monkey Platelet and T Cell Activation Antigen 1(PTA1).
DNA Sequence 1999; 10: 155-161
15 Huang Chuanshu, Jin Boquan, Wang Meixian, Li Enshan. Study
on the activated antigen expression on the lymphocytes
and
lymphoblasts from HFRS patients. Shanhai Mian Yi Xue Zha Zhi
1991;11:94-96
16 Su Min, Niu Shumiao, Tian Dongping, Li Jian, Li Hengli, Guo
Shangwen, Shi Bingyin. The clinical significance of aberrant
HLA-DR
antigen expression on thyrocytes. Zhonghua Bing Li Xue Za Zhi
1994;23:34-36
17 Tabata H, Hara M, Kitani A, Hirose T, Norioka K, Harigai M,
Suzuki K, Kawakami M, Kawagoe M, Nakamura H.
Hirose-T
Expression of TLiSA1 on T cells from patients with rheumatoid
arthritis and systemic lupus erythematosus.
Clin
Immunol Immunopathol 1989;52:366-375
18 Miller FW, Love LA, Barbieri SA, Balow JE, Plotz PH.
Lymphocyte activation markers in idiopathic myositis: changes
with
disease
activity and differences among clinical and autoantibody
subgroups. Clin Exp Immunol 1990; 81:373-379
19 Huang Chuanshu, Jin Boquan, Wang Meixian, Li Enshan, Sun
Chen. Hemorrhagic fever with renal syndrome:
relationship
between pathogenesis and cellular immunity. J Infect Dis
1994;169:868-870
20 Loertscher R, Forbes RD, Halabi G, Lavery P, Quinn T.
Expression of early and late activation markers on peripheral
blood
T lymphocytes does not reliably reflect immune events in
transplanted hearts. Clin Transplant 1994;8:230-238
21 Sun Kai, Jin Boquan, Sun Chen, Tian Fang, Zhu Yong, Yang
Kun, Liu Xuesong. Construction and expression of a novel
human
platelet/T cell activation antigen 1(PTA1) fusion protein in COS-7
cells. Xi Bao Yu Fen Zi Mian Yi Xue Zha
Zhi
1998;14:1-4
22 Lena Serghides, Ian Crandall, Eric Hull, and Kevin C. Kain.
The Plasmodium falciparum-CD36 Interaction Is Modified by
a
Single Amino Acid
Substitution in CD36. Blood 1998;92:1814-1819
23 Sun Kai, Jin Boquan, Sun Chen, Zhu Yong, Jia Wei, Yang Kun,
Liu Chenggang. Purification of PTA1/Ig fusion protein by
affinity
chromatography for PTA1. Xi Bao Yu Fen Zi Mian Yi Xue Zha Zhi
1998;14:113-116
24 Callen DF, Baker E, Eyre HJ, Chernos JE, Bell JA,
Sutherland GR. Reassessment of two apparent deletions of
chromosome
16p to an ins(11;16) and a
t(1;16) by chromosome painting. Ann Genet 1990;33:219-221
25 Hawke NA, Yoder JA, Litman GW. Expanding our understanding
of immunoglobulin, T-cell antigen receptor, and
novel
immune-type receptor genes: a subset of the immunoglobulin gene
superfamily. Immunogenetics
1999;50:124-133
26 Linsley PS, Peach R, Gladstone P, Bajorath J. Extending the
B7 (CD80) gene family. Protein Sci 1994;3:1341-1343
27 Taheri M, Saragovi U, Fuks A, Makkerh J, Mort J, Stanners
CP. Self recognition in the Ig superfamily. Identification of
precise
subdomains in carcinoembryonic antigen required for intercellular
adhesion. J Biol Chem
2000;275:26935-26943
28 Bierer BE, Sleckman BP, Ratnofsky SE, Burakoff SJ.The
biologic roles of CD2, CD4, and CD8 in T-cell activation. Annu
Rev
Immunol 1989;7:579-599
29 Kupfer A, Singer SJ. Cell biology of cytotoxic and helper T
cell functions: immunofluorescence microscopic studies of
single
cells and cell couples. Annu
Rev Immunol 1989;7:309-337
30 Springer TA, Dustin ML, Kishimoto TK, Marlin SD.The
lymphocyte function-associated LFA-1, CD2, and LFA-3
molecules:
cell
adhesion receptors of the immune system. Annu Rev Immunol
1987;5:223-252
31 Dustin ML, Sanders ME, Shaw S, Springer TA.Purified
lymphocyte function-associated antigen 3 binds to CD2 and
mediates
T lymphocyte adhesion. J Exp Med 1987;165:677-692
32 Kishimoto TK, O’Connor K, Lee A, Roberts TM, Springer TA.
Cloning of the beta subunit of the leukocyte adhesion
proteins:
homology to an extracellular matrix receptor defines a novel
supergene family. Cell 1987;48:681-690
33 Shibuya K, Lanier LL, Phillips JH, Ochs HD, Shimizu K,
Nakayama E, Nakauchi H, Shibuya A.Physical and functional
association
of LFA-1 with DNAM-1 adhesion
molecule. Immunity 1999;11:615-623
34 Shibuya A, Lanier LL, Phillips JH. Protein kinase C is
involved in the regulation of both signaling and adhesion
mediated
by
DNAX accessory molecule-1 receptor. J Immunol
1998;161:1671-1676
35 Isobe M, Suzuki J, Yamazaki S, Yazaki Y, Horie S, Okubo Y,
Maemura K, Yazaki Y, Sekiguchi M.Regulation by differential
development
of Th1 and Th2 cells in peripheral tolerance to cardiac allograft
induced by blocking ICAM-1/LFA-1
adhesion.
Circulation 1997;96:2247-2253
36 Gunji Y, Nakamura M, Hagiwara T, Hayakawa K, Matsushita H,
Osawa H, Nagayoshi K, Nakauchi H, Yanagisawa M,
Miura
Y, et al.Expression and
function of adhesion molecules on human hematopoietic stem cells:
CD34+ LFA-1- cells
are
more primitive than CD34+
LFA-1+ cells. Blood 1992;80:429-436
37 Hogg N, Landis RC.Adhesion molecules in cell interactions.
Curr Opin Immunol 1993;5:383-390
38 Springer TA. Adhesion receptors of the immune system.
Nature 1990;346:425-434
39 Phillips JH, McKinney L, Azuma M, Spits H, Lanier LL. A
novel beta 4, alpha 6 integrin-associated epithelial cell
antigen
involved
in natural killer cell and antigen-specific cytotoxic T
lymphocyte cytotoxicity. J Exp Med 1991;174:1571-1581
40 Adler B, Ashkar S, Cantor H, Weber GF. Costimulation by
extracellular matrix proteins determines the response to TCR
ligation.
Cell Immunol 2001;210:30-40
41 Park WR, Park CS, Tomura M, Ahn HJ, Nakahira Y, Iwasaki M,
Gao P, Abe R, Hamaoka T, Fujiwara H. CD28
costimulation
is required not only to
induce IL-12 receptor but also to render janus kinases/STAT4
responsive to IL-12
stimulation
in TCR-triggered T cells. Eur
J Immunol 2001;31:1456-1464
42 Clavreul A, Fisson S, D’hellencourt CL, Couez D.
Interelationship between CD3 and CD28 pathways in a murine T cell
thymoma.
Mol Immunol 2000;37:571-577
43 Aruffo A, Seed B. Molecular cloning of a CD28 cDNA by a
high-efficiency COS cell expression system. Proc Natl Acad Sci
U
S A 1987;84:8573-8577
44 Seed B, Aruffo A. Molecular cloning of the CD2 antigen, the
T-cell erythrocyte receptor, by a rapid immunoselection
procedure.
Proc Natl Acad Sci U S A 1987;84:3365-3369
45 Sewell WA, Brown MH, Dunne J, Owen MJ, Crumpton MJ.
Molecular cloning of the human T-lymphocyte surface CD2
(T11)
antigen. Proc Natl Acad Sci U S A 1986;83:8718-8722
46 Wilson GL, Fox CH, Fauci AS, Kehrl JH. cDNA cloning of the
B cell membrane protein CD22: a mediator of B-B cell
interactions. J
Exp Med 1991;173:137-146
47 Wyler B, Daviet L, Bortkiewicz H, Bordet JC, McGregor JL.
Cloning of the cDNA encoding human platelet CD36:
comparison
to PCR amplified
fragments of monocyte, endothelial and HEL cells. Thromb Haemost
1993;70:500-505
48 Ianelli CJ, Edson CM, Thorley-Lawson DA. A ligand for human
CD48 on epithelial cells. J Immunol 1997;159:3910-3920
49 Koopman G, Keehnen RM, Lindhout E, Zhou DF, de Groot C,
Pals ST. Germinal center B cells rescued from apoptosis by
CD40
ligation or attachment to follicular dendritic cells, but not by
engagement of surface immunoglobulin or adhesion
receptors,
become resistant to CD95-induced apoptosis. Eur J Immunol
1997;27:1-7
50 Piepkorn M, Hovingh P, Bennett KL, Aruffo A, Linker
A.Chondroitin sulphate composition and structure in
alternatively
spliced
CD44 fusion proteins. Biochem J 1997;327:499-506
51 Lee JW, Gersuk GM, Kiener PA, Beckham C, Ledbetter JA, Deeg
HJ. HLA-DR-triggered inhibition of hemopoiesis involves
Fas/Fas
ligand interactions and is prevented by c-kit ligand. J Immunol
1997;159:3211-3219
52 Zollner O, Lenter MC, Blanks JE, Borges E, Steegmaier M,
Zerwes HG, Vestweber D. L-selectin from human, but not
from
mouse neutrophils binds directly to E-selectin. J Cell Biol
1997;136:707-716
53 Mannori G, Santoro D, Carter L, Corless C, Nelson RM,
Bevilacqua MP. Inhibition of colon carcinoma cell lung colony
formation
by a soluble form of E-selectin.
Am J Pathol 1997;151:233-243
54 Dmitrieva N, Shelton D, Rice AS, McMahon SB. The role of
nerve growth factor in a model of visceral inflammation.
Neuroscience
1997;78:449-459
55 Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray
GS, Hong X, Thomas D, Fechner JH Jr, Knechtle SJ.
CTLA4-Ig
and anti-CD40 ligand prevent renal allograft rejection in
primates. Proc Natl Acad Sci U S A
1997;94:8789-8794
56 Moreland LW, Baumgartner SW, Schiff MH, Tindall EA,
Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman
WJ,
Mohler K, Widmer MB,
Blosch CM.Treatment of rheumatoid arthritis with a recombinant human
tumor necrosis
factor
receptor (p75)-Fc fusion
protein. N Engl J Med 1997;337:141-147
57 Jin Boquan, Scott JL, Vadas MA, Burns GF. TGF beta
down-regulates TLiSA1 expression and inhibits the
differentiation
of
precursor lymphocytes into CTL and LAK cells. Immunology
1989;66:570-576
58 O’Rourke AM, Mescher MF. Cytotoxic T-lymphocyte
activation involves a cascade of signalling and adhesion events.
Nature
1992;358:253-255
59 Rodrigues M, Nussenzweig RS, Romero P, Zavala F. The in
vivo cytotoxic activity of CD8+ T cell clones correlates with
their
levels of expression of
adhesion molecules. J Exp Med 1992;175:895-905
| |